Abstract
It has become common clinical practice to combine the selective serotonin reuptake inhibitors with other serotonergic agents for augmentation or adjunctive purposes. The empirical basis for using these combinations remains limited, but is growing. Also growing is a literature that suggests that even the most apparently benign combinations of serotonergic drugs carry at least some risk of serious pharmacokinetic or pharmacodynamic drug interactions, such as a serotonin syndrome.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antidepressive Agents / administration & dosage*
-
Antidepressive Agents / therapeutic use
-
Depressive Disorder / drug therapy*
-
Drug Synergism
-
Drug Therapy, Combination
-
Humans
-
Monoamine Oxidase Inhibitors / administration & dosage
-
Monoamine Oxidase Inhibitors / therapeutic use
-
Selective Serotonin Reuptake Inhibitors / administration & dosage*
-
Selective Serotonin Reuptake Inhibitors / therapeutic use
-
Serotonin Antagonists / administration & dosage
-
Serotonin Antagonists / therapeutic use
-
Serotonin Receptor Agonists / administration & dosage
-
Serotonin Receptor Agonists / therapeutic use
Substances
-
Antidepressive Agents
-
Monoamine Oxidase Inhibitors
-
Serotonin Antagonists
-
Serotonin Receptor Agonists
-
Serotonin Uptake Inhibitors